Targeted nanoparticles a promising opportunity in cancer therapy – Review

Nanoparticles as drug delivery vehicles pose an exciting and promising future for cancer treatment, and offer particular benefits not only for cancer treatment, but also for overcoming of multidrug resistance in cancer tissues. Targeted delivery of anti-neoplastic drugs by nanoparticles promises enhanced drug efficacy, selectivity and reduced systemic toxicity. Nanoparticle systems have unique properties that allow for both passive and active targeting of tumors. Active targeting of nanoparticles, that usually involve surface proteins known to be upregulated in cancer cells, increases accumulation in a tumor. Targeting molecules include antibodies or their fragments, aptamers, or small molecules. This review describes a comprehensive overview of different targeting of nanodrugs.

1. Aslan, B.; Ozpolat, B.; Sood, A.K.; Lopez-Berestein, G. Nanotechnology in cancer therapy, J Drug Target 2013, 21, 904–13.
2. Ediriwickrema, A.; Saltzman, W.M. Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Th erapies, ACS Biomater Sci Eng 2015, 1, 64–78.
3. Danhier, F.; Feron, O.; Pré at, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J Control Release 2010, 148, 135−46.
4. Dawidczyk, C.M.; Russell, L.M.; Searson, P.C. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments, Front Chem 2014, 2, 69.
5. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy, Nat Nanotechnol 2007, 2, 751−60.
6. Alibolandi, M.; Ramezani, M.; Abnous, K.; Sadeghi, F.; Atyabi, F.; Asouri, M., et al. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer, J Control Release 2015, 209, 88–100.
7. Yang, Z.; Tang, W.X.; Luo, X.G.; Zhang, X.F.; Zhang, C.; Li, H., et al. Dual-Ligand Modifi ed Polymer-Lipid Hybrid Nanoparticles for Docetaxel Targeting Delivery to Her2/neu Overexpressed Human Breast Cancer Cells, J Biomed Nanotechnol 2015, 11, 1401–17.
8. Shan, L.; Liu, M.; Wu, C.; Zhao, L.; Li, S.; Xu, L., et al. Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy, Int J Nanomedicine 2015, 10, 5571–91.
9. Goren, D.; Horowitz, A.T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance effl ux pump, Clin Cancer Res 2000, 6, 1949–57.
10. Pan, X.; Lee, R.J. Tumour-selective drug delivery via folate receptor-targeted liposomes, Expert Opin Drug Deliv 2004, 1, 7–17.
11. Guo, L.; Zhang, H.; Wang, F.; Liu, P.; Wang, Y.; Xia, G., et al. Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system, Int J Nanomedicine 2015, 10, 4535–47.
12. Liang, M.; Fan, K.; Zhou, M.; Duan, D.; Zheng, J.; Yang, D., et al. H-ferritin-nanocaged doxorubicin nanoparticles specifi cally target and kill tumors with a single-dose injection, Proc Natl Acad Sci 2014, 111, 14900–5.
13. Cao, Y.; Zhou, Y.; Zhuang, Q.; Cui, L.; Xu, X.; Xu, R., et al. Anti-tumor eff ect of RGD modifi ed PTX loaded liposome on prostatic cancer, Int J Clin Exp Med 2015, 8, 12182–91
14. Arachchige, M.C.; Reshetnyak, Y.K.; Andreev, O.A. Advanced targeted nanomedicine, J Biotechnol 2015, 202, 88–97
15. Lee, S.J.; Shim, Y.H.; Oh, J.S.; Jeong, Y.I.; Park, I.K.; Lee, H.C. Folic-acid-conjugated pullulan/ poly(DL-lactide-co-glycolide) graft copolymer nanoparticles for folate-receptor-mediated

PDF